FDA Approved: RYSTIGGO — Supplemental Application (UCB, Inc.)

View source ↗

Summary

FDA approved a supplemental application for RYSTIGGO (rozanolixizumab) from UCB, Inc., supporting an updated indication or labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myasthenia Gravis

Drugs mentioned

• RYSTIGGO (rozanolixizumab)

Snippet

SUPPL AP for RYSTIGGO (ROZANOLIXIZUMAB)